Literature DB >> 19291371

Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model.

Xulang Zhang1, Chee Guan Koh, Bo Yu, Shujun Liu, Longzhu Piao, Guido Marcucci, Robert J Lee, L James Lee.   

Abstract

PURPOSE: Transferrin (Tf) conjugated lipopolyplexes (LPs) carrying G3139, an antisense oligonucleotide for Bcl-2, were synthesized and evaluated in Tf receptor positive K562 erythroleukemia cells and then in a murine K562 xenograft model.
MATERIALS AND METHODS: Particle size and Zeta potentials of transferrin conjugated lipopolyplexs containing G3139 (Tf-LP-G3139) were measured by Dynamic Light Scattering and ZetaPALS. In vitro and in vivo sample's Bcl-2 downregulation was analyzed using Western blot and tumor tissue samples also exhibited by immunohistochemistry method. For athymic mice bearing with K562 xenograft tumors, tumor growth inhibition and survival rate were investigated. Nanoparticle distribution in 3-D cell cluster was observed by Laser scan confocal microscopy. IL-12 production in the plasma was measured by ELISA kit.
RESULTS: In vitro, Tf-LP-G3139 was more effective in inducing down regulation of Bcl-2 in K562 cells than non-targeted LP-G3139, free G3139 and mismatched control ODN-G4126 in the same formulation. In vivo Tf-LP-G3139 was less effective than free G3139 in Bcl-2 down regulation. 3-D cell cluster model diffusion results indeed indicated limited penetration of the LPs into the cell cluster. Finally, the therapeutic efficacies of Tf-LP-G3139 and free G3139 were determined in the K562 xenograft model. Tf-LP-G3139 showed slower plasma clearance, higher AUC, and greater accumulation in the tumor compared to free G3139. In addition, Tf-LP-G3139 was found to be more effective in tumor growth inhibition and prolonging mouse survival than free G3139. This was associated with increased spleen weight and IL-12 production in the plasma.
CONCLUSION: The role of the immune system in the therapeutic response obtained with the Tf-LPs is necessary and in vitro 3-D cell cluster model can be a potential tool to evaluate the nanoparticle distribution.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19291371      PMCID: PMC3800032          DOI: 10.1007/s11095-009-9864-8

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

Review 1.  CpG motifs in bacterial DNA and their immune effects.

Authors:  Arthur M Krieg
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

Review 2.  A fresh look at tumor immunosurveillance and immunotherapy.

Authors:  M J Smyth; D I Godfrey; J A Trapani
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

Review 3.  CpG motifs: the active ingredient in bacterial extracts?

Authors:  Arthur M Krieg
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

4.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

5.  Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes.

Authors:  W M Li; M B Bally; M P Schutze-Redelmeier
Journal:  Vaccine       Date:  2001-10-12       Impact factor: 3.641

6.  Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.

Authors:  B Mui; S G Raney; S C Semple; M J Hope
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

7.  Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.

Authors:  Daniel E Lopes de Menezes; Lawrence D Mayer
Journal:  Cancer Chemother Pharmacol       Date:  2002-01       Impact factor: 3.333

8.  Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts.

Authors:  L Xu; K F Pirollo; W H Tang; A Rait; E H Chang
Journal:  Hum Gene Ther       Date:  1999-12-10       Impact factor: 5.695

9.  Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.

Authors:  Xiaojuan Yang; Chee Guan Koh; Shujun Liu; Xiaogang Pan; Ramasamy Santhanam; Bo Yu; Yong Peng; Jiuxia Pang; Sharon Golan; Yeshayahu Talmon; Yan Jin; Natarajan Muthusamy; John C Byrd; Kenneth K Chan; L James Lee; Guido Marcucci; Robert J Lee
Journal:  Mol Pharm       Date:  2009 Jan-Feb       Impact factor: 4.939

10.  Antisense oligonucleotides reach mRNA targets via the RNA matrix: downregulation of the 5-HT1A receptor.

Authors:  Fuxin Shi; Willy H Visser; Natasja M J de Jong; Robert S B Liem; Eric Ronken; Dick Hoekstra
Journal:  Exp Cell Res       Date:  2003-12-10       Impact factor: 3.905

View more
  12 in total

1.  Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells.

Authors:  Jiang Chang; Archibald Paillard; Catherine Passirani; Marie Morille; Jean-Pierre Benoit; Didier Betbeder; Emmanuel Garcion
Journal:  Pharm Res       Date:  2011-12-14       Impact factor: 4.200

2.  A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide delivery.

Authors:  Xiaojuan Yang; Yong Peng; Bo Yu; Jianhua Yu; Chenguang Zhou; Yicheng Mao; L James Lee; Robert J Lee
Journal:  Mol Pharm       Date:  2011-03-23       Impact factor: 4.939

Review 3.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

Review 4.  Intratumoral drug delivery with nanoparticulate carriers.

Authors:  Hillary Holback; Yoon Yeo
Journal:  Pharm Res       Date:  2011-01-07       Impact factor: 4.200

5.  Disulfide-linked liposomes: effective delivery vehicle for Bcl-2 antisense oligodeoxyribonucleotide G3139.

Authors:  Wanlop Weecharangsan; Bo Yu; Shujun Liu; Jiu Xia Pang; L James Lee; Guido Marcucci; Robert J Lee
Journal:  Anticancer Res       Date:  2010-01       Impact factor: 2.480

6.  Lipid-based nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma.

Authors:  Longzhu Piao; Manchao Zhang; Jharna Datta; Xiujie Xie; Tizhi Su; Hong Li; Theodoros N Teknos; Quintin Pan
Journal:  Mol Ther       Date:  2012-04-10       Impact factor: 11.454

7.  Nanoparticle formulations that allow for sustained delivery and brain targeting of the neuropeptide oxytocin.

Authors:  Rokon Uz Zaman; Nihal S Mulla; Keegan Braz Gomes; Cherilyn D'Souza; Kevin Sean Murnane; Martin J D'Souza
Journal:  Int J Pharm       Date:  2018-07-19       Impact factor: 5.875

8.  Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.

Authors:  Xiaomeng Huang; Sebastian Schwind; Bo Yu; Ramasamy Santhanam; Hongyan Wang; Pia Hoellerbauer; Alice Mims; Rebecca Klisovic; Alison R Walker; Kenneth K Chan; William Blum; Danilo Perrotti; John C Byrd; Clara D Bloomfield; Michael A Caligiuri; Robert J Lee; Ramiro Garzon; Natarajan Muthusamy; Ly James Lee; Guido Marcucci
Journal:  Clin Cancer Res       Date:  2013-03-14       Impact factor: 12.531

9.  Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid.

Authors:  Shravan Kumar Sriraman; Giusseppina Salzano; Can Sarisozen; Vladimir Torchilin
Journal:  Eur J Pharm Biopharm       Date:  2016-06-02       Impact factor: 5.571

10.  Nanoparticle encapsulation increases the brain penetrance and duration of action of intranasal oxytocin.

Authors:  Aboagyewaah Oppong-Damoah; Rokon Uz Zaman; Martin J D'Souza; Kevin Sean Murnane
Journal:  Horm Behav       Date:  2018-12-30       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.